Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis

30 August 2024 (09:05 - 09:15)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Mr Steven Anton Muller

University Medical Center Utrecht, Utrecht (Netherlands (The))

4 More presentations in this session

Presentation thumbnail

Patient characteristics and incidence of cardiac amyloidosis: an observational study in the UK clinical setting using electronic health records

Doctor L. Anderson (London, GB)

Abstract Slides Video

Presentation thumbnail

Usefulness of scintigraphy with [99mTc]Tc-DPD for the detection of transthyretin cardiac amyloidosis. Reference centre experience in an endemic area.

Doctor N. Orta (Palma de Mallorca, ES)

Abstract Slides Video

Presentation thumbnail

Cardiac magnetic resonance T1 imaging for the diagnosis of cardiac amyloidosis among patients with symptomatic heart failure

Doctor R. Gessner (Leipzig, DE)

Abstract Slides Video

Presentation thumbnail

Prevalence and prognostic significance of restriction versus systolic dysfunction in patients with transthyretin and light chain cardiac amyloidosis

Doctor M. Zampieri (Florence, IT)

Abstract Slides Video

Access the full session

Session thumbnail

Cardiac amyloidosis: my heart is filled with so much…

The Event

Event poster

ESC Congress 2024

30 August 2024 09:05 CET

You may be interested in

Congress Presentation

Highlights from family screening and treatment with Vutrisiran for heriditary transthyretin cardiac amyloidosis

Congress Presentation

Family screening in hereditary transthyretin cardiac amyloidosis

Congress Session

Cardiac amyloidosis: my heart is filled with so much…

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources